DrugPatentWatch Database Preview

Eluxadoline - Generic Drug Details

« Back to Dashboard

What are the generic sources for eluxadoline and what is the scope of eluxadoline patent protection?

Eluxadoline is the generic ingredient in one branded drug marketed by Allergan Holdings and is included in one NDA. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eluxadoline has one hundred and thirty-two patent family members in thirty-seven countries.

There are two drug master file entries for eluxadoline. One supplier is listed for this compound.

Summary for eluxadoline

International Patents:	132
US Patents:	13
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	2
Suppliers / Packagers:	1
Bulk Api Vendors:	21
Clinical Trials:	4
Patent Applications:	24
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for eluxadoline
DailyMed Link:	eluxadoline at DailyMed

Pharmacology for eluxadoline

Drug Class	mu-Opioid Receptor Agonist
Mechanism of Action	Opioid mu-Receptor Agonists

Synonyms for eluxadoline

45TPJ4MBQ1

5-(((S)-2-AMINO-3-(4-CARBAMOYL-2,6-DIMETHYLPHENYL)-N-((S)-1-(4-PHENYL-1H-IMIDAZOL-2-YL)ETHYL)PROPANAMIDO)METHYL)-2-METHOXYBENZOIC ACID

5-(((S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-((S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic acid

5-({(4-carbamoyl-2,6-dimethyl-L-phenylalanyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid

5-[[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[(1S)-1-(4-phenyl-3H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid

864821-90-9

AC-30329

AKOS030632800

AS-35135

Benzoic acid, 5-((((2S)-2-amino-3-(4-(aminocarbonyl)-2,6-dimethylphenyl)-1-oxopropyl)((1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl)amino)methyl)-2-methoxy-

CHEBI:85980

CHEMBL2159122

CS-3855

D10403

DB09272

DEA No. 9725

DTXSID70235589

Eluxadoline (USAN)

Eluxadoline [USAN:INN]

EX-A1169

FT-0701295

GTPL7691

HY-12247

J3.535.064K

JNJ 27018966

JNJ-27018966

JNJ27018966

NCGC00485958-01

SB17335

SCHEMBL12971682

SCHEMBL17950908

truberzi

UNII-45TPJ4MBQ1

Viberzi

Viberzi (TN)

ZINC14210876

US Patents and Regulatory Information for eluxadoline

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan Holdings	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015		RX	Yes	No			Y
Allergan Holdings	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015		RX	Yes	Yes
Allergan Holdings	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015		RX	Yes	Yes			Y

International Patents for eluxadoline

Country	Patent Number	Estimated Expiration
Costa Rica	11260
Canada	2695126
Spain	2428008

Supplementary Protection Certificates for eluxadoline

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1725537	LUC00007	Luxembourg		PRODUCT NAME: ELUXADOLINE OU UN ENANTIOMERE, UN DIASTEREOMERE, UNRACEMATE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/16/1126 20160921
2176234	122017000010	Germany		PRODUCT NAME: ELUXADOLIN; REGISTRATION NO/DATE: EU/1/16/1126 20160919
1725537	2017/007	Ireland		PRODUCT NAME: ELUXADOLINE OR A PHARMACEUTICALLY ACCEPTABLE ENANTIOMER, DIASTEREOMER, RACEMATE OR SALT THEREOF; REGISTRATION NO/DATE: EU/1/16/1126 20160919